The latest price target for Repligen (NASDAQ:RGEN) was reported by HC Wainwright & Co. on January 23, 2025. The analyst firm set a price target for $180.00 expecting RGEN to rise to within 12 months (a possible 6.51% upside). 15 analyst firms have reported ratings in the last year.

The latest analyst rating for Repligen (NASDAQ:RGEN) was provided by HC Wainwright & Co., and Repligen maintained their buy rating.

The last upgrade for Repligen Corp happened on June 26, 2024 when Deutsche Bank raised their price target to $155. Deutsche Bank previously had a hold for Repligen Corp.

The last downgrade for Repligen Corp happened on December 4, 2023 when Benchmark changed their price target from N/A to N/A for Repligen Corp.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Repligen, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Repligen was filed on January 23, 2025 so you should expect the next rating to be made available sometime around January 23, 2026.

While ratings are subjective and will change, the latest Repligen (RGEN) rating was a maintained with a price target of $240.00 to $180.00. The current price Repligen (RGEN) is trading at is $169.00, which is out of the analyst’s predicted range.